🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

L’estudi espanyol #DapaTAVI mostra que en els pacients a qui s’ha implantat TAVI, la dapagliflozina va reduir la incidència de mort per qualsevol causa o empitjorament de la insuficiència cardíaca NEJM Sergio Raposeiras-Roubín Borja Ibanez CNIC Ander Regueiro #ACC25

Delighted to have presented the first Phase 2 trial of solbinsiran a siRNA targeting ANGPTL3 a key regular of Triglyceride metabolism. Despite ldl lowering patients with high TG have a high residual risk of CVD.

Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: Over ten years of efficacy and safety data - Journal of Clinical Lipidology lipidjournal.com/article/S1933-…

Post hoc AIM-HIGH trial "GLYCA were associated significantly with the residual risk of both CVD events and mortality, and mortality risk was incrementally increased by ⏬ levels of the SMALL HDL PARTICLE subclass known to have antioxidative and anti-inflammatory properties"

A pujar escales !!! cdn.jwplayer.com/previews/2LYwQ…

A single combined measure of LDL cholesterol, hsCRP, and Lp(a) among initially healthy individuals was predictive of incident MACE during a 20-year period. Read the results of the EPIC-Norfolk study in #EHJ 👉 ow.ly/MVQ950Vvjwu Rocco Montone EHJ Editor-in-Chief #prevention

🔴Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease @EurHeartJ #CardioTwitter #LipidScience #MedEd ✅ PRO view: TG-rich lipoproteins (TRLs) are more than just TG carriers—they’re cholesterol-loaded,

L’Hospital Universitari Sant Joan de Reus 📍 va acollir, ahir divendres 11 d’abril, un curs avançat en trastorns lipídics rars. Organitzat per la Societat Europea d’Aterosclerosi (EAS), és un esdeveniment de referència en lipidologia avançada i diagnòstic de precisió. 🔗 salutsantjoan.cat/ca/noticies-i-…

🥁Ya tenemos disponible el Documento de Consenso sobre la planificación de la terapia hipolipemiante en la EVA Soc Esp Cardiología Cardiología Preventiva Asociación Cardiología Clínica SEC Arterias Sanas Sociedad SEEN semFYC SEMERGEN | Médicos de Atención Primaria SEMG 🩺 #OrgullososDeEstarALaCabecera👩‍⚕️👨‍⚕️ S.E.N. Nefrología Sociedad Española de Angiología y Cirugía Vascular SEN Asociación CI y Cuidados Agudos Cardiovasculares

Treatment of heterozygous familial hypercholesterolaemia in children: is lower better? academic.oup.com/eurjpc/article…

Top 5 advances in medicine this week (🧵) 1. Doctors vs. AI This is an experiment where patient actors spoke either with a doctor or an AI chatbot (made by Google Research) by typing back and forth - they didn't know which they were speaking to AI won for diagnostic accuracy,

For very high risk women: a mini-discussion - "Is statin therapy safe for pregnant women?" cardiovascularbusiness.com/topics/clinica… National Lipid Association European Atherosclerosis Society ASPC European Society of Cardiology International Atherosclerosis Society (IAS) Family Heart Foundation Foundation of the NLA FH Europe Foundation

EU life expectancy hits 81.4 years, exceeding pre-COVID level ec.europa.eu/eurostat/produ…

🙌Game-changing real-world data from SWEDEHEART! 📰Leosdottir et al., JACC 2024 jacc.org/doi/10.1016/j.… Title: Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes 👩‍🦰🧑‍🦰Population: >71,000 post-MI patients on high-intensity

Daily movement may not feel like exercise — but it matters more than you think. New data from 24,000+ non-exercisers shows: - Just 4–5 min/day of vigorous activity - Or ~24 min/day of moderate activity Was enough to cut the risk of cardiovascular events (including deaths) by

The new issue of the European Journal of Preventative Cardiology focuses on "Lifestyle and Cardiovascular Diseases". Read the introductory Editorial on the capital importance of lifestyle and diet in cardiovascular disease prevention: academic.oup.com/eurjpc/article… European Society of Cardiology Victor Aboyans

The mean reduction was 19.5% with highest dose, which is less that the typical 25% reduction with antibodies. Thus far, it seems oral PCSK9i do not seem as potent as the antibodies in lowering LDL-C, so I would expect a lesser effect on Lp(a) lowering in concert.

Intensive LDL-C lowering with Evolocumab may lead to greater relative reduction in cardiovascular events in patients with autoimmune or inflammatory diseases. André Zimerman @bweber04 ana laura kunzler @rgiuglaino ahajournals.org/doi/full/10.11…

Breaking! Phase 3 ESSENCE trial results just out: Semaglutide 2.4 mg showed significant improvements for adults with #MASH-63% achieved resolution of steatohepatitis with no worsening of fibrosis vs. 34% on placebo at 72 weeks. #LiverHealth nejm.org/doi/full/10.10… NEJM

Dia de la concienciación sobre la hipercolesterolemia familiar homocigota. Una enfermedad minoritaria que debemos detectar en la infancia. Midamos el colesterol a los niños.